<DOC>
	<DOCNO>NCT02943369</DOCNO>
	<brief_summary>Platelets thrombus formation play key role pathogenesis acute coronary artery occlusion subsequent myocardial infarction . Apart mechanically open occlude artery angioplasty , adjunctive antiplatelet treatment utmost importance . However , orally administer antiplatelet agent exhibit delay onset action set acute myocardial infarction angioplasty mostly perform without adequate platelet inhibition . Cangrelor intravenous antiplatelet agent provide almost immediate strong platelet inhibition . The investigator aim compare strategy cangrelor administer top ticagrelor-an oral antiplatelet agent- v ticagrelor alone , efficacy inhibit platelet function early hour acute myocardial infarction .</brief_summary>
	<brief_title>Cangrelor Following Ticagrelor Loading v Ticagrelor Loading Alone STEMI</brief_title>
	<detailed_description>A rapid consistent platelet inhibition represent cornerstone pharmacological treatment early hour ST-segment elevation myocardial infarction ( STEMI ) expect improvement outcome . Current practice guideline recommend administration load dose ( LD ) oral P2Y12 receptor antagonist early possible time percutaneous coronary intervention ( PCI ) first medical contact . Pharmacodynamic data clearly show delay onset action prasugrel ticagrelor administer patient STEMI - compare obtain stable acute coronary syndrome ( ACS ) patients- , likely cause impaired absorption . Peri-interventional platelet inhibition therefore suboptimal case timely perform primary PCI , even novel oral antiplatelet agent faster clopidogrel action use . Modifications load dose antiplatelet pre-hospital administration may partially 'bridge gap '' platelet inhibition . On hand , cangrelor parenteral P2Y12 antagonist , rapid -within minutes- onset action , able provide strong consistent platelet inhibition rapid offset action- within 60 min infusion discontinuation . In CHAMPION PHOENIX ( Cangrelor Versus Standard Therapy Achieve Optimal Management Platelet Inhibition ) trial cangrelor reduce incidence ischemic event , without increase incidence severe bleeding . Ticagrelor oral antiplatelet agent report give infusion cangrelor without attenuation cangrelor 's pharmacodynamic effect , pharmacodynamic effect ticagrelor preserve ticagrelor give infusion cangrelor . It seem therefore , ticagrelor favorable characteristic patient intend receive cangrelor . In present study , STEMI patient undergo primary PCI investigator aim compare platelet inhibition achieve patient load ticagrelor follow cangrelor ( bolus plus infusion ) v ticagrelor alone load patient . This prospective , randomize , 3-center , single-blind , investigator-initiated study parallel design compare platelet inhibition provide ticagrelor LD plus cangrelor ( bolus infusion ) v ticagrelor LD alone . Participants consecutive P2Y12 inhibitor-naive STEMI patient pain onset &lt; 12 hour admit primary PCI consider . Participants arm receive ticagrelor 180 mg LD early possible ( e.g . speak hospital case transfer emergency department case hub hospital presentation ) , per local practice . The exact time ticagrelor administration record . Randomization follow immediate initiation cangrelor administration perform angiography immediately prior PCI . Patients randomize ( Hour 0 ) 1:1 ratio independent investigator cangrelor 30 mcg/kg bolus + 4 mcg/kg/min 2 hour , IV antiplatelet . Other treatment per local standard care participant . Investigators perform platelet function test blind actual treatment assignment , whereas independent investigator monitor bleed adverse event data . Platelet reactivity measure randomization ( Hour 0 ) 15 min , 1 , 2 4 hour post randomization . Platelet function test perform VerifyNow ( Accumetrics Inc , San Diego , CA ) point-of-care P2Y12 function assay within 30 min blood sample collection . Platelet reactivity result report P2Y12 reaction unit ( PRU ) % inhibition . The % inhibition calculate : ( [ BASE−PRU ] /BASE ) ×100 . High platelet reactivity ( HPR ) define ≥208 PRU .</detailed_description>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Consecutive P2Y12 inhibitornaive STEMI patient pain onset &lt; 12 hour admit primary PCI . history stroke/transient ischemic attack bleed diathesis chronic oral anticoagulation treatment contraindication anti platelet therapy PCI coronary artery bypass graft &lt; 3 month platelet count &lt; 100 000/μL hematocrit &lt; 30 % creatinine clearance &lt; 30 mL/min severe hepatic dysfunction use strong CYP3A inhibitor inducer increase risk bradycardia severe chronic obstructive pulmonary disease periprocedural IIb/IIIa inhibitor administration .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cangrelor</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>P2Y12 receptor antagonist</keyword>
	<keyword>acute myocardial infarction</keyword>
</DOC>